Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12147383 | 0.91 | PTGDR2 (0.47) | HTTTSHRGAASMN1; SMN2PTGDR2 | |
| SCHEMBL12147382 | 0.90 | PTGDR2 (0.46) | HTTTSHRGAASMN1; SMN2PTGDR2 | |
| SCHEMBL12147389 | 0.88 | PTGDR2 (0.72) | HTTTSHRGAASMN1; SMN2PTGDR2 | |
| SCHEMBL12147262 | 0.87 | PTGDR2 (0.53) | HTTPTGDR2KMT2A | |
| SCHEMBL13261435 | 0.86 | PTGDR2 (0.57) | HTTPTGDR2ALDH1A1KDM4E | |
| SCHEMBL13261375 | 0.84 | PTGDR2 (0.55) | HTTSMN1; SMN2PTGDR2MEN1KMT2A | |
| SCHEMBL12147472 | 0.84 | PTGDR2 (0.54) | PTGDR2 | |
| SCHEMBL12147467 | 0.84 | PTGDR2 (0.57) | PTGDR2 | |
| SCHEMBL12147380 | 0.83 | PTGDR2 (0.58) | HTTTSHRGAASMN1; SMN2PTGDR2 | |
| SCHEMBL13261446 | 0.83 | PTGDR2 (0.49) | PTGDR2MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273769-B2 | Phenoxy acetic acid derivatives | MERCK SERONO SA (CH) | 2012-09-25 | — | — | US | disclosed |
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-11-24 | — | — | US | disclosed |
| WO-2010092043-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | HRH2, HRH1, HRH3 | HTT 4078/4885TSHR 3579/4885GAA 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.